Blog
RSS FeedPosted by Michael Wonder on 14 Jan 2019
US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy
14 January 2019 - FDA grants a priority review based on Phase 3 ATTR-ACT study findings. ...
Posted by Michael Wonder on 11 Jan 2019
US FDA sets PDUFA date for Scenesse
10 January 2019 - FDA does not plan to hold advisory committee meeting. ...
Posted by Michael Wonder on 06 Dec 2018
Federal officials call out FDA over lapses in rare-disease drug approval
5 December 2018 - The 1983 Orphan Drug Act motivated pharmaceutical companies to develop drugs for people who lacked treatments ...
Posted by Michael Wonder on 03 Dec 2018
FDA faulted for lapses in orphan drug program
30 November 2018 - The FDA has failed to ensure that drugs given prized rare-disease status meet the intent of ...
Posted by Michael Wonder on 01 Dec 2018
‘A loss for the rest of us’: An FDA approval is a boon for a drug maker, but could come at a major cost for patients
30 November 2018 - Vickie Moored can walk again. Her words don’t slur, her vision isn’t blurred, and she no ...
Posted by Michael Wonder on 29 Nov 2018
FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare auto-immune disorder
28 November 2018 - The U.S. FDA today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in adults. ...
Posted by Michael Wonder on 20 Nov 2018
FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease
20 November 2018 - The U.S. FDA today approved Gamifant (emapalumab) for the treatment of paediatric (newborn and above) and ...
Posted by Michael Wonder on 06 Oct 2018
FDA approves Revcovi, a new enzyme replacement therapy developed by Leadiant Biosciences, for the treatment of ADA-SCID in paediatric and adult patients
5 October 2018 - Leadiant Biosciences today announced that the FDA has granted approval to Revcovi (elapegademase-lvlr) injection in the ...
Posted by Michael Wonder on 19 Sep 2018
Can patient advocates help make Akcea the next Sarepta and overcome the FDA’s rejection?
18 September 2018 - Patients with a rare disease are asking the FDA a question the agency rarely hears: Is ...
Posted by Michael Wonder on 15 Sep 2018
Single FDA centre fo rare diseases could be 'negative' to rare disease cause
14 September 2018 - FDA's Center for Drug Evaluation and Research Director Janet Woodcock advised against a single FDA Centre of ...
Posted by Michael Wonder on 21 Aug 2018
Audentes announces regenerative medicine advanced therapy designation granted by the FDA to AT132 for the treatment of X-linked myotubular myopathy
21 August 2018 - Designation granted based on positive interim data from ASPIRO clinical trial. ...
Posted by Michael Wonder on 21 Aug 2018
FDA accepts priority review of ALXN1210 as a treatment for patients with paroxysmal nocturnal haemoglobinuria in the US
20 August 2018 - EU filing accepted and under review. ...
Posted by Michael Wonder on 16 Aug 2018
FDA approves Kalydeco (ivacaftor) as first and only medicine to treat the underlying cause of CF in children ages 12 to <24 months with certain mutations in the CFTR gene
15 August 2018 - Data from Phase 3 ARRIVAL study support treatment with Kalydeco in children ages 12 to <24 months. ...
Posted by Michael Wonder on 13 Aug 2018
Amicus sets $315,000 price for new Fabry disease treatment
13 August 2018 - Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry ...
Posted by Michael Wonder on 11 Aug 2018
FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
10 August 2018 - The U.S. FDA today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused ...